Table 6.
Significant factors other than HLA locus matching for clinical outcomes
| Outcomes, Significant factor (P < .01) | N | RR | 95% CI | P |
|---|---|---|---|---|
| Acute GVHD (grade III-IV) | ||||
| Patient age, year linear | 7898 | 0.99 | 0.99-1.00 | <.001 |
| Disease | ||||
| ALL (Ref.) | 1861 | 1.00 | ||
| Aplastic anemia | 489 | 0.41 | 0.26-0.64 | <.001 |
| Conditioning | ||||
| Myeloablative (Ref.) | 6653 | 1.00 | ||
| Reduced intensity | 1245 | 1.26 | 1.07-1.50 | .007 |
| Sex matching | ||||
| Female to male (Ref.) | 1494 | 1.00 | ||
| Female to female | 1442 | 0.77 | 0.64-0.92 | .005 |
| Chronic GVHD | ||||
| Patient age, year linear | 6528 | 1.01 | 1.00-1.01 | <.001 |
| Donor age, year linear | 6528 | 1.00 | 1.00-1.00 | <.001 |
| Disease | ||||
| ALL (Ref.) | 1568 | 1.00 | ||
| CML | 813 | 1.28 | 1.13-1.46 | <.001 |
| Aplastic anemia | 425 | 0.64 | 0.46-0.89 | .008 |
| Transplanted year | ||||
| 1993-2000 (Ref.) | 1865 | 1.00 | ||
| 2006-2010 | 2117 | 0.74 | 0.65-0.83 | <.001 |
| Leukemia relapse | ||||
| Disease | ||||
| ALL (Ref.) | 1861 | 1.00 | ||
| CML | 983 | 0.49 | 0.39-0.60 | <.001 |
| Leukemia risk | ||||
| Standard (Ref.) | 2508 | 1.00 | ||
| High | 2772 | 2.62 | 2.31-2.98 | <.001 |
| Transplanted year | ||||
| 1993-2000 (Ref.) | 1815 | 1.00 | ||
| 2001-2005 | 2079 | 1.34 | 1.14-1.56 | <.001 |
| 2006-2010 | 1559 | 1.31 | 1.09-1.57 | .004 |
| Neutrophil engraftment | ||||
| Disease | ||||
| ALL (Ref.) | 1831 | 1.00 | ||
| CML | 959 | 0.90 | 0.84-0.97 | .005 |
| GVHD prophylaxis | ||||
| Cyclosporin based (Ref.) | 2998 | 1.00 | ||
| Tacrolimus based | 4716 | 1.12 | 1.07-1.18 | <.001 |
| Leukemia risk | ||||
| Standard (Ref.) | 2486 | 1.00 | ||
| High | 2703 | 0.81 | 0.77-0.85 | <.001 |
| Sex matching | ||||
| Female to male (Ref.) | 1462 | 1.00 | ||
| Male to male | 3182 | 1.10 | 1.03-1.16 | .002 |
| Male to female | 1686 | 1.12 | 1.05-1.20 | .001 |
| ABO blood type matching | ||||
| Match (Ref.) | 3455 | 1.00 | ||
| Major mismatch | 1452 | 0.88 | 0.83-0.94 | <.001 |
| Transfused nuclear cell no./weight, kg, ×10E8 | ||||
| <2.0 (Ref.) | 1038 | 1.00 | ||
| 2.0-4.0 | 4999 | 1.34 | 1.26-1.42 | <.001 |
| ≤4.0 | 1068 | 1.42 | 1.31-1.55 | <.001 |
| Mortality | ||||
| Patient age, year linear | 7898 | 1.02 | 1.02-1.02 | <.001 |
| Donor age, year linear | 7898 | 1.01 | 1.01-1.02 | <.001 |
| Disease | ||||
| ALL (Ref.) | 1861 | 1.00 | ||
| AML | 2609 | 0.81 | 0.74-0.89 | <.001 |
| CML | 983 | 0.72 | 0.63-0.81 | <.001 |
| MDS | 841 | 0.50 | 0.40-0.64 | <.001 |
| Other leukemia | 312 | 0.68 | 0.52-0.89 | .005 |
| Lymphoid malignancy | 542 | 0.54 | 0.42-0.70 | <.001 |
| Aplastic anemia | 489 | 0.30 | 0.23-0.40 | <.001 |
| Leukemia risk | ||||
| Standard (Ref.) | 2508 | 1.00 | ||
| High | 2772 | 2.19 | 2.01-2.39 | <.001 |
| Sex matching | ||||
| Female to male (Ref.) | 1494 | 1.00 | ||
| Female to female | 1442 | 0.81 | 0.72-0.90 | <.001 |
| Transplanted year | ||||
| 1993-2000 (Ref.) | 2311 | 1.00 | ||
| 2001-2005 | 3084 | 0.81 | 0.74-0.89 | <.001 |
| 2006-2010 | 2503 | 0.67 | 0.60-0.75 | <.001 |
Multivariable competing risk regression analyses were conducted to evaluate the impact of acute GVHD, chronic GVHD, leukemia relapse and neutrophil engraftment, and a Cox proportional regression model for mortality. RR of respective factors was compared with the reference factor adjusted by HLA locus matching and clinical factors. Factors with significance (P < .01) were listed. RR of all variables is shown in supplemental Table 6.
Ref., reference factor.